CoChat

Second-generation antipsychotics for obsessive compulsive disorder

Komossa, Katja, Depping, Anna M, Meyer, Magdalena, Kissling, Werner, Leucht, Stefan · 2010 · Cochrane Database of Systematic Reviews
Cited by 96

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Obsessive compulsive disorder (OCD) is a psychiatric disorder which has been shown to affect 2 to 3.5% of people during their lifetimes. Inadequate response occurs in 40% to 60% of people that are prescribed first line pharmaceutical treatments (selective serotonin reuptake inhibitors (SSRIs)). To date not much is known about the efficacy and adverse effects of second-generation antipsychotic drugs (SGAs) in people suffering from OCD. OBJECTIVES: To evaluate the effects of SGAs (monotherapy or add on) compared with placebo or other forms of pharmaceutical treatment for people with OCD. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on ClinicalTrials.gov and contacted key authors and drug companies. SELECTION CRITERIA: We included double-blind randomised controlled trials (RCTs) comparing oral SGAs (monotherapy or add on) in adults with other forms of pharmaceutical treatment or placebo in people with primary OCD. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD), again based on a random-effects model. MAIN RESULTS: We included 11 RCTs with 396 participants on three SGAs. All trials investigated the effects of adding these SGAs to antidepressants (usually SSRIs). The duration of all trials was less than six months. Only 13% of the participants left the trials early. Most trials were limited in terms of quality aspects.Two trials examined olanzapine and found no difference in the primary outcome (response to treatment) and most other efficacy-related outcomes but it was associated with more weight gain than monotherapy with antidepressants.Quetiapine combined with antidepressants was also not any more efficacious than placebo combined with antidepressants in terms of the primary outcome, but there was a significant superiority in the mean Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score at endpoint (MD -2.28, 95% CI -4.05 to -0.52). There were also some beneficial effects of quetiapine in terms of anxiety or depressive symptoms.Risperidone was more efficacious than placebo in terms of the primary outcome (number of participants without a significant response) (OR 0.17, 95% CI 0.04 to 0.66) and in the reduction of anxiety and depression (MD -7.60, 95% CI -12.37 to -2.83). AUTHORS' CONCLUSIONS: The available data of the effects of olanzapine in OCD are too limited to draw any conclusions. There is some evidence that adding quetiapine or risperidone to antidepressants increases efficacy, but this must be weighed against less tolerability and limited data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008141.pub2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 40

  1. Geus, 2007, Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder, International Clinical Psychopharmacology, 22, 77, 10.1097/YIC.0b013e32801182f7 · DOI
  2. Ezegovesi, 2005, Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study, European Neuropsychopharmacology, 15, 69, 10.1016/j.euroneuro.2004.04.004 · DOI
  3. Kordon, 2008, Quetiapin addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 28, 550, 10.1097/JCP.0b013e318185e735 · DOI
  4. Baxter, 2002, Adjunctive risperidone in the treatment of SSRI-refractory obsessive-compulsive disorder, International Journal of Neuropsychopharmacology, 5, 132
  5. Shapira, 2004, A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder, Biological Psychiatry, 550, 553, 10.1016/j.biopsych.2003.11.010 · DOI
  6. Vulink, 2009, Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled study of 76 patients, Journal of Clinical Psychiatry online publication, 70, 1001, 10.4088/JCP.08m04269 · DOI
  7. Atmaca, 2002, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study, International Clinical Psychopharmacology, 17, 115, 10.1097/00004850-200205000-00004 · DOI
  8. D'Amico, 2003, Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder, Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 619, 10.1016/S0278-5846(03)00050-2 · DOI
  9. Denys, 2002, Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study, Journal of Clinical Psychiatry, 63, 700, 10.4088/JCP.v63n0807 · DOI
  10. Koran, 2000, Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder, Journal of Clinical Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI
  11. Liu, 2005, Comparative analysis of risperidone combining with paroxetine in treatment of obsessive compulsive disorder, Journal of Clinical Psychological Medicine, 15, 17
  12. Maina, 2008, 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder, European Neuropsychopharmacology, 18, 364, 10.1016/j.euroneuro.2008.01.001 · DOI
  13. Mohr, 2002, Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder, International Clinical Psychopharmacology, 17, 37, 10.1097/00004850-200201000-00006 · DOI
  14. Pigott, 1992, A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 12, 11, 10.1097/00004714-199202000-00003 · DOI · Paper page
  15. Stein, 1997, Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders, Journal of Clinical Psychiatry, 58, 119, 10.4088/JCP.v58n0306 · DOI · Paper page
  16. Yang, 2002, A comparative study on the efficacy of combining risperidone and fluoxetine in the treatment of refractory obsessive compulsive disorder, Chinese Journal of Behavioural Medical Science, 11, 402
  17. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III)
  18. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition- Revised (DSM-III-R)
  19. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
  20. Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 63, 10.1016/S0893-133X(97)00112-7 · DOI · Paper page
  21. Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
  22. Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006531 · DOI
  23. Correll, 2004, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies, American Journal of Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 · DOI · Paper page
  24. Der-Simonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  25. Goodwin, 2009, Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus Meeting, March 2008, Nice, European Neuropsychopharmacology, 19, 520, 10.1016/j.euroneuro.2009.04.003 · DOI
  26. Gulliford, 1999, Components of variance and intra class correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
  27. Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
  28. Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  29. Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
  30. Hawkridge, 2009, Pharmacotherapy for anxiety disorders in children and adolescents, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005170.pub2 · DOI · Paper page
  31. Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
  32. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  33. Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008 · DOI · Paper page
  34. Ipser, 2006, Pharmacotherapy augmentation strategies in treatment resistant augmentation disorders, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005473.pub2 · DOI
  35. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  36. Ravindran, 2007, Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders, Expert Opinion in Pharmacotherapy, 8, 1693, 10.1517/14656566.8.11.1693 · DOI
  37. Sajatovic, 2003, Treatment for mood and anxiety disorders: quetiapine and aripiprazole, Current Psychiatry Reports, 5, 320, 10.1007/s11920-003-0062-9 · DOI
  38. Vital, 2007, Seroquel led antipsychotics sales in 2006, Clinical Psychiatric News, 35, 1
  39. World Health Organization, 1992, International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
  40. Zaudig, 2002, Epidemiology, comorbidity and course of obsessive compulsive disorder

Cited by

See all 96

Metadata

Authors
Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-12-08
Issue
12
Pages
CD008141-CD008141
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1588248498
Cited by
96
References
19
FWCI
7.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second-generation antipsychotics for obsessive compulsive disorder. https://app.cochat.ai/papers/10.1002/14651858.cd008141.pub2
The paper
Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S. (2010). Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008141.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.